Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor.

Literature DB >> 23648912

An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor.

Nicholas G Wysham¹, Donald R Sullivan², Gopal Allada³.

Abstract

We report a case of Cryptococcus neoformans pneumonia in a patient taking ruxolitinib, a janus kinase 1,2 inhibitor approved for the treatment of myelofibrosis. We hypothesize that ruxolitinib contributed to this infection through its effects on cell-mediated immunity. Clinicians should be aware of the potential for intracellular or opportunistic infections associated with this novel drug class.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2013 PMID： 23648912 PMCID： PMC5991580 DOI： 10.1378/chest.12-1604

Source DB: PubMed Journal: Chest ISSN： 0012-3692 Impact factor: 9.410

6 in total

1. Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms.

Authors: Ayalew Tefferi
Journal: N Engl J Med Date: 2012-03-01 Impact factor: 91.245

2. Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis.

Authors: Ken Garber
Journal: Nat Biotechnol Date: 2011-06-07 Impact factor: 54.908

3. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

Authors: Srdan Verstovsek; Ruben A Mesa; Jason Gotlib; Richard S Levy; Vikas Gupta; John F DiPersio; John V Catalano; Michael Deininger; Carole Miller; Richard T Silver; Moshe Talpaz; Elliott F Winton; Jimmie H Harvey; Murat O Arcasoy; Elizabeth Hexner; Roger M Lyons; Ronald Paquette; Azra Raza; Kris Vaddi; Susan Erickson-Viitanen; Iphigenia L Koumenis; William Sun; Victor Sandor; Hagop M Kantarjian
Journal: N Engl J Med Date: 2012-03-01 Impact factor: 91.245

Review 4. Cryptococcal interactions with the host immune system.

Authors: Kerstin Voelz; Robin C May
Journal: Eukaryot Cell Date: 2010-04-09

5. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry.

Authors: D Salmon-Ceron; F Tubach; O Lortholary; O Chosidow; S Bretagne; N Nicolas; E Cuillerier; B Fautrel; C Michelet; J Morel; X Puéchal; D Wendling; M Lemann; P Ravaud; X Mariette
Journal: Ann Rheum Dis Date: 2010-12-21 Impact factor: 19.103

6. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.

Authors: William J Sandborn; Subrata Ghosh; Julian Panes; Ivana Vranic; Chinyu Su; Samantha Rousell; Wojciech Niezychowski
Journal: N Engl J Med Date: 2012-08-16 Impact factor: 91.245

6 in total

52 in total

1. Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function.

Authors: F Perner; T M Schnöder; S Ranjan; D Wolleschak; C Ebert; M C Pils; S Frey; A Polanetzki; C Fahldieck; U Schönborn; B Schraven; B Isermann; T Fischer; F H Heidel
Journal: Leukemia Date: 2015-08-05 Impact factor: 11.528

Review 2. Immunological Consequences of JAK Inhibition: Friend or Foe?

Authors: Donal P McLornan; Alesia A Khan; Claire N Harrison
Journal: Curr Hematol Malig Rep Date: 2015-12 Impact factor: 3.952

Review 3. Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.

Authors: Brady L Stein; Jason Gotlib; Murat Arcasoy; Marie Huong Nguyen; Neil Shah; Alison Moliterno; Catriona Jamieson; Daniel A Pollyea; Bart Scott; Martha Wadleigh; Ross Levine; Rami Komrokji; Rebecca Klisovic; Krishna Gundabolu; Patricia Kropf; Meir Wetzler; Stephen T Oh; Raul Ribeiro; Rita Paschal; Sanjay Mohan; Nikolai Podoltsev; Josef Prchal; Moshe Talpaz; David Snyder; Srdan Verstovsek; Ruben A Mesa
Journal: J Natl Compr Canc Netw Date: 2015-04 Impact factor: 11.908

An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor.

1. Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms.

2. Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis.

3. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

Review 4. Cryptococcal interactions with the host immune system.

5. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry.

6. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.

1. Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function.

Review 2. Immunological Consequences of JAK Inhibition: Friend or Foe?

Review 3. Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.

Review 4. Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?

Review 5. The Rationale for Immunotherapy in Myeloproliferative Neoplasms.

6. Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib.

Review 7. Efficacy of ruxolitinib for myelofibrosis.

8. Disseminated tuberculosis associated with ruxolitinib.

9. Fungal immunology in clinical practice: Magical realism or practical reality?

Review 10. Clinical potential of pacritinib in the treatment of myelofibrosis.